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Abstract
Purpose We investigated whether impaired patterns of myo-
cardial fatty acid imaging were associated with cardiac death
in dialysis patients without coronary lesions.
Methods We prospectively enrolled 155 hemodialysis pa-
tients without obstructive coronary artery disease, who had
been examined by single-photon emission computed tomog-
raphy (SPECT) using the iodinated fatty acid analogue
BMIPP. Uptake of BMIPP on SPECT was graded in 17 seg-
ments on a five-point scale (0, normal; 4, absent) and assessed
as BMIPP summed scores. Of the enrolled 155 participants,
we analyzed 95 who had BMIPP summed scores ≥ 6 (52 men
and 43 women, 65±11 years). BMIPP scores ≥ 2 in ≥ 2 con-
secutive segments in SPECT were defined as focal, and the
others as non-focal pattern.
Results Of 95 participants analyzed, 42 (44.2 %) showed fo-
cal and 53 (55.8 %) non-focal type. During follow-up for 5.1±
2.0 years, 42 died of cardiac events. The occurrence of cardiac
death was higher in the focal than in the non-focal group (30/
42 [71.4%] versus 12/53 [22.6%], p=0.001). In stepwise Cox
hazard analysis, focal pattern was associated with cardiac
death (hazard ratio 2.266), independent of impairment of
BMIPP SPECT (BMIPP summed scores ≥ 12). The predictive
potential of BMIPP SPECT for cardiac death was higher
(p<0.001) in the left anterior descending artery area compared
with other coronary territories.
Conclusions Focal impairment in myocardial fatty acid imag-
ing in the left anterior descending area may strongly predict
cardiac death in this population.
Keywords Fatty acid imaging .Microcirculation .
Myocardial infarction . Scintigraphy . Sudden death
Introduction
Deaths of cardiac origin play an important role in the high
mortality of patients with end-stage renal disease who undergo
renal replacement therapy [1].We have shown that visualizing
impaired myocardial fatty acid metabolism by single-photon
emission computed tomography (SPECT) using the iodinated
fatty acid analogue, iodine-123-β-methyl iodophenyl-
pentadecanoic acid (BMIPP), can help to identify patients at
high risk of cardiac death among asymptomatic patients on
hemodialysis who have not been treated by coronary interven-
tion [2], and among those with coronary revascularization
achieved by percutaneous coronary intervention [3]. This pre-
dictive potential of BMIPP SPECT for cardiac death in hemo-
dialysis patients was identified in a multicenter cohort study in
Japan (B-SAFE) [4]. Obstructive coronary artery disease
(CAD) is undoubtedly involved in cardiac deaths induced by
acute myocardial infarction (MI) or congestive heart failure
(CHF) and in sudden cardiac death (SCD); however, cardiac
deaths can occur in patients on hemodialysis without CAD
[5]. Although myocardial fatty acid imaging reveals focal
and non-focal impairment, it has not been elucidated whether
either of these impaired pattern types of fatty acid imaging are
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involved in cardiac deaths of hemodialysis patients. In the
present study, we investigated whether the impaired patterns
of myocardial fatty acid imaging are associated with the car-
diac deaths in hemodialysis patients without obstructive CAD,
and further examined whether the predictive potential of im-
paired fatty acid imaging for cardiac deaths differed in the
perfusion areas of the three coronary arteries.
Material and methods
Study population This study was based on the data of a
previously reported cohort study [6]. Among these data, 422
patients on maintenance hemodialysis at the Toujinkai group
underwent coronary angiography (CAG) for the first time to
determine the presence or absence of CAD between 1 January
2001 and 31 December 2004. The Toujinkai group includes
Toujinkai Hospital, Toujinkai Clinic, and Toujinkai Satellite
Clinic, Kyoto, Japan. No significant stenotic coronary lesions
(Diameter stenosis greater than 50 %) were identified in 205
of the 422 patients. Among the 205, 50 patients were excluded
from the study based on the reasons described in Fig. 1. Pa-
tients were not included in the study if they had a history of
acute MI or invasive coronary artery intervention such as cor-
onary artery bypass grafting or percutaneous coronary inter-
vention, or unrecognized old MI without obstructive CAD
identified as significantly reduced uptake on 201Thallium
(Tl) SPECT images. Further, patients with CHF of NYHA
grades III to IV, moderate or worse valvular heart disease,
permanent pacemaker implantation or idiopathic cardiomyop-
athy were not included. Consequently, 155 hemodialysis pa-
tients without significant obstructive coronary lesions were
enrolled in this cohort study. The participants were enrolled
at the time of homeostatic model assessment of insulin resis-
tance (HOMA-IR) measurements (between 1 January 2001
and 31 December 2004), and followed through 31 December
2008 until the endpoint described below was reached. Of the
155 subjects, 95 hemodialysis patients with abnormal BMIPP
SPECT findings (BMIPP summed scores [SS] ≥ 6) were en-
rolled in the analysis (52 men, 43 women; age, 65±11 years;
mean dialysis duration, 87±99 months); BMIPP SS ≥ 6 indi-
cated the presence of myocardial ischemia in our previous
study [7], and it was possible for us to distinguish between
focal and non-focal types in the analysis of SPECT. Figure 1
summarizes entry and exclusion criteria for the study. The
Ethics Committee for Human Research of Toujinkai Hospital
approved this study, and all patients provided written in-
formed consent for all procedures associated with the study
prior to participation. The study was performed in accordance
with the principles of the Declaration of Helsinki, and regis-
tered to the ClinicalTrials.gov (https://clinicaltrials.gov/):
protocol identifier, NCT01068080.
Radionuclide imagingAll patients underwent resting BMIPP
and Tl dual myocardial scintigraphy after fasting for over
6 hours on a midweek, non-dialysis day within one month
before the first CAG. Patients were injected at rest intrave-
nously with 111-MBq of 123I-BMIPP (Nihon Medi-Physics,
Tokyo, Japan) and 111 MBq of 201Tl (Nihon Medi-Physics).
Details of the dual BMIPP-Tl SPECT procedure are described
elsewhere [2–4, 6, 7]. The images of the left ventricle were
divided into 17 segments for semiquantitative analysis, and
coronary perfusion territories of these 17 segments were de-
termined according to the standard myocardial segmentation
422 hemodialysis patients who had received coronary 
angiography (CAG) between January 1, 2001 and December 
31, 2004 23 patients: 
1) Patients who had not done BMIPP-Tl SPECT within 
      one month of CAG (n=6)
2) Congestive heart failure (New York Heart Association 
     grades 3 to 4) (n=5)
3) Significant valvular heart disease (n=4)
4) Pacemaker (n=2)
5) Pulmonary disease (n=2)
6) Idiopathic hypertrophic or dilated cardiomyopathy (n=3)
7) Malignancy (n=1)
27 patients:
1) Patients who had not done measured HOMA-IR within 
      one month after CAG (n=8)
2) Patients receiving extrinsic insulin or medication of  
     sulfonylurea (n=19)
Enrolled: 155 hemodialysis patients
     (89 men, 66 women; 64±11years)
Follow-up: through December 31, 2008
Analysis: 95 hemodialysis patients with BMIPP summed score 
                of 6 or more
     (52 men, 43 women; 65±11years)
205 patients without stenotic coronary lesions
Excluded
Excluded
Fig. 1 Entry and exclusion of study participants
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for tomographic heart imaging established by the American
Heart Association [8]. The amount of radioactivity taken up
by each segment was visually graded and assigned an
uptake score of 0 (normal), 1 (mildly reduced), 2 (moder-
ately reduced), 3 (severely reduced), or 4 (none). The
BMIPP and Tl SPECT scores for 17 myocardial segments
were designated as summed BMIPP and Tl scores, respec-
tively. A perfusion metabolic mismatch score between
BMIPP and Tl in a whole SPECT was obtained as
BMIPP SS minus Tl SS, and BMIPP-Tl mismatch score
in each coronary territory was obtained as total BMIPP
score minus total Tl score in that territory. The same ex-
perienced technician performed all scintigraphic proce-
dures. All BMIPP and Tl SPECT images were interpreted
within one week of the SPECT examination by the same
two investigators who were blinded to clinical and labora-
tory information about the patients. The inter-observer and
intra-observer variability in the BMIPP SS at our institute
was 6.8±1.4 % and 5.4±1.4 %, respectively. Patients were
divided into two groups according to the myocardial im-
aging patterns in BMIPP SPECT. The focal pattern was
defined as BMIPP defect scores ≥ 2 in ≥ 2 consecutive
left ventricular segments. Minimally impaired uptake
(BMIPP score ≤ 1) or multiple small defects with the size
of each defect ≤ 1 segment but BMIPP scores ≥ 2 were
defined as non-focal.
Echocardiography The patients underwent two-
dimensionally guided echocardiography using a single ultra-
sonographic recorder (UF-8800, Fukuda Denshi, Tokyo,
Japan) on a midweek non-dialysis day within one month be-
fore CAG. Left ventricular dimensions and left ventricular
ejection fraction (LVEF) were quantified using the biplanar
Simpson’s rule, and left ventricular mass was measured as
recommended by the American Society of Echocardiography
[9]. Left ventricular mass was normalized to body surface
area, and is described herein as left ventricular mass index.
Biochemical and hematological determinations On a mid-
week dialysis day within 30 days after CAG, blood samples
(10 ml) were obtained in the morning from patients who had
fasted overnight and rested for 10 min. Blood hemoglobin,
plasma concentrations of intact parathyroid hormone and B-
type natriuretic peptide, and serum concentrations of calcium,
inorganic phosphorus, albumin, total cholesterol, and C-
reactive protein were determined.
Assessment of insulin resistance We used fasting plasma
glucose and fasting plasma insulin concentrations to calculate
the HOMA-IR: fasting glucose concentration (mmol/L) ×
fasting insulin concentration (μU/ml)/22.5. Blood samples
were collected on the same day to measure other biochemical
and hematological parameters.
Endpoint The endpoint was cardiac-derived death, that is,
SCD or death due to acute MI or CHF. We defined SCD as
death within 24 hours of the time that the patient was last seen
alive in a normal state of health and for which a cardiac dis-
ease such as malignant arrhythmia or acute coronary syn-
drome was considered the cause. Cerebrovascular accidents
were ruled out by post-mortem examinations. Acute MI was
diagnosed when new abnormal Q waves appeared on electro-
cardiogram together with anterior chest pain or discomfort,
when abnormal left ventricular wall motion was recognized
on echocardiogram, and when serum concentrations of
troponin-T and creatine phosphokinase-MB fraction were sig-
nificantly elevated. Death due to CHF was diagnosed when
the patients had died of primary heart failure of cardiac origin;
the patients who had died of secondary heart failure following
acute MI or who died in a state of chronic excess fluid accom-
panied with non-cardiac diseases were not included. Blinded
investigators within the Toujinkai group or Kyoto Second Red
Cross Hospital adjudicated all endpoints.
Statistical analysis Values are expressed as means±SD. We
compared the means of continuous variables using non-paired
t tests. Categorical data were analyzed using the χ2 test. Prog-
nosis was assessed using univariate and multivariate Cox pro-
portional hazards models. Covariates that were significant in
univariate Cox hazard analyses (p<0.05) were assessed by
stepwise Cox hazard analyses. We examined event-free sur-
vival using the Kaplan-Meier method and the log-rank test.
p values of<0.05 were considered significant. The predictive
potential for cardiac death was compared among the total
BMIPP scores in the coronary artery territories using receiver
operating characteristic (ROC) analysis. All data were statis-
tically analyzed by individuals who were blinded to any clin-
ical information about the patients. All statistical analyses
were performed with SAS software version 8.2.
Results
Of the 95 enrolled patients analyzed, focal pattern in BMIPP
SPECTwas recognized in 42 patients (44.2 %) and non-focal
pattern in 53 patients (55.8 %). Figure 2 shows representative
cases of focal and non-focal pattern in BMIPP SPECT. Table 1
shows baseline clinical characteristics in the focal and non-
focal groups. The mean BMIPP SS was higher in the focal
than in the non-focal group, whereas the mean Tl SS did not
differ between the two groups. The percentages of BMIPP SS
≥ 12, a cutoff value of predicting cardiac death in our previous
studies [2, 6], were higher in the focal than in the non-focal
group.
Cardiac deaths and fatty acid imaging patterns Of the 95
enrolled patients, 42 (44.2 %) died of cardiac events (acute
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MI, n=7; CHF, n=18; SCD, n=17) and 14 (14.7 %) died of
non-cardiac causes (malignancy, n=5; infectious diseases, n=
3; cerebrovascular accidents, n=3; respiratory diseases, n=1;
hepatic diseases, n=1; gastrointestinal bleeding, n=1) during
follow-up. The incidences of cardiac deaths were higher in the
focal than in the non-focal group (30/42, 71.4 % versus 12/53,
22.6 %; p <0.001). Compared with the non-focal group, the
focal group showed higher incidence of all cause deaths and
cardiac deaths induced by acute MI or SCD; however, the
incidence of CHF death did not differ between focal and
non-focal groups (Table 2). In univariate Cox hazard analysis
for cardiac deaths, age, HOMA-IR, BMIPP SS, BMIPP SS ≥
12, and focal pattern in BMIPP SPECT were positively, and
body mass index and serum albumin concentration were in-
versely associated with cardiac deaths (Table 3). In stepwise
Cox hazard analysis for cardiac deaths among age, body mass
index, serum albumin, HOMA-IR, BMIPP SS ≥ 12, or focal
pattern in BMIPP SPECT, focal pattern in BMIPP SPECTwas
associated with cardiac deaths independently of BMIPP SS ≥
12 (Table 4).
In Kaplan-Meier survival analysis, cardiac death-free sur-
vival rates for 5 years were lower in the focal than in the non-
focal group (43.7 % versus 77.2%, p=0.001) (Fig. 3). Among
the types of cardiac deaths, the focal group showed lower
event-free survival rates than the non-focal group in acute
MI death (5 years: 77.0 % versus 100 %, p=0.001) or SCD
(5 years: 69.8 % versus 94.4 %, P=0.002); however, event-
free survival rate of CHF death did not differ between the focal
and non-focal groups (5 years: 81.3 % versus 81.7 %, p=
0.933) (Fig. 4).
Impaired fatty acid imaging and cardiac deaths in the
coronary artery territories Among 42 patients of the focal
group, 20 patients showed focally reduced uptake of
BMIPP in SPECT in the single coronary artery area; right
coronary artery (RCA), n=7; left anterior descending artery
(LAD), n=6; left circumflex artery (LCX), n=7. The other
22 patients showed focally reduced uptake of BMIPP in the
multiple coronary artery areas; RCA+LAD, n=9; LAD+
LCX, n=8; RCA+LCX, n=2; RCA+LAD+LCX, n=3.
Consequently, focally reduced uptake of BMIPP in the
RCA, LAD, or LCX area was recognized in 21/42
(50.0 %), 26/42 (61.9 %), or 20/42 (47.6 %), respectively.
In univariate Cox hazard analysis, focally reduced uptake
of BMIPP in SPECT was significantly associated with car-
diac death in the LAD area (hazard ratio, 3.152; 95 % CI,
1.276-7.786, p=0.013), but not in the RCA (hazard ratio,
1.086; 95 % CI, 0.524-2.253, p=0.824) or LCX area (risk
ratio, 0.726; 95 % CI, 0.346-1.525; p=0.398). The mean
total BMIPP scores in the coronary perfusion areas of the
focal group were higher than those of non-focal group in
the LAD area (10.5±6.4 versus 4.3±2.1, p <0.001), but not
in either the RCA (3.5±3.6 versus 4.0±2.2, p=0.676) or
LCX area (3.4±4.5 versus 3.6±2.7, p=0.956). In univariate
Cox hazard analysis, total BMIPP scores in the coronary
territories were significantly associated with cardiac death
in the LAD area (hazard ratio, 1.092; 95 % CI, 1.047-1,
139; p<0.001), but not in the RCA (hazard ratio, 0.998;
95 % CI, 0.895-1.114; p=0.977) or LCX area (hazard ratio,
1.069; 95 % CI, 0.991-1.153; p=0.083). In the ROC anal-
ysis, the predictive potential of coronary territorial BMIPP
Fig. 2 BMIPP SPECT images of
focal (A) and non-focal (B)
patterns. A Focal pattern of
BMIPP SPECT. a BMIPP
summed score 20 (right coronary
artery area 15, left anterior
descending artery area 3, left
circumflex artery area 2), b
BMIPP summed score 30 (right
coronary artery area 6, left
anterior descending artery area
18, left circumflex artery area 6);
B Non-focal pattern of BMIPP
SPECT. a BMIPP summed score
8 (right coronary artery area 4, left
anterior descending artery area 3,
left circumflex artery area 1), b
BMIPP summed score 17 (right
coronary artery area 6, left
anterior descending artery area 6,
left circumflex artery area 5)
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scores for cardiac deaths was higher (p<0.001) in the LAD
area than the LCX or RCA areas (Fig. 5).
Perfusion metabolic mismatch and cardiac death Of 95
patients, BMIPP SS was higher than Tl SS in 94. One patient
showed lower BMIPP SS than Tl SS; total BMIPP scores
were lower than total Tl scores in the LAD (three versus four)
and RCA (two versus eight) areas. No other patients showed
higher Tl score than BMIPP score in any coronary territorial
area. The predictive potential of BMIPP-Tl mismatch score
Table 1 Differences in clinical







Age, years 68.2±10.7 62.8±10.4 0.022
Male gender, n (%) 29 (69.0) 23 (43.4) 0.013
Dialysis duration, months 83.8±95.3 88.8±103.1 0.651
Smoking habit, n (%) 17 (40.5) 17 (32.1) 0.396
Alcohol consumption, n (%) 17 (40.5) 16 (30.2) 0.296
Diabetes mellitus, n (%) 17 (40.5) 19 (35.8) 0.644
Systolic blood pressure before dialysis, mm Hg 143.2±13.0 144.9±17.1 0.527
Diastolic blood pressure before dialysis, mm Hg 77.7±21.9 81.5±20.0 0.583
Body mass index, kg/m2 20.7±4.2 21.6±4.3 0.596
Cardiothoracic ratio, % 52.6±6.0 53.0±4.7 0.731
Left ventricular ejection fraction, % 57.1±17.9 63.2±13.1 0.112
Left ventricular mass index, g/m2 142.5±45.3 144.9±17.1 0.527
Blood hemoglobin, g/L 103.2±8.8 104.0±12.1 0.860
Serum albumin, g/L 37.8±3.2 37.8±3.8 0.885
Serum calcium, mmol/L 2.3±0.2 2.3±0.2 0.835
Serum inorganic phosphorus, mmol/L 1.6±0.4 1.7±0.3 0.372
Serum total cholesterol, mmol/L 4.3±0.8 4.5±0.9 0.627
Log serum intact parathyroid hormone, ng/L 2.3±0.4 2.2±0.3 0.492
Serum C-reactive protein, mg/L 4.2±3.4 3.8±2.7 0.697
Log plasma B-type natriuretic peptide, pg/ml 2.4±0.5 2.3±0.4 0.882
HOMA-IR, mmol/L·μU/ml 5.7±2.0 5.4±2.0 0.446
BMIPP summed scores 17.4±9.0 12.0±5.2 <0.001
BMIPP summed scores ≧12, n (%) 30 (71.4) 26 (49.1) 0.028
Tl summed scores 6.3±4.1 6.7±4.7 0.694
Medications
α1 blockers, n (%) 4 (9.5) 5 (9.5) 1.000
β blockers, n (%) 13 (31.0) 16 (30.2) 0.936
Calcium channel blockers, n (%) 15 (35.7) 15 (28.3) 0.644
ACEI, n (%) 0 (0) 2 (3.8) 0.502
ARB, n (%) 11 (26.2) 16 (30.2) 0.668
Nitrates, n (%) 3 (7.1) 9 (17.0) 0.152
Antiplatelet drugs, n (%) 24 (57.1) 26 (49.1) 0.433
Anticoagulation drugs, n (%) 1 (2.4) 0 (0) 0.442
Statins, n (%) 9 (21.4) 14 (26.4) 0.573
Vitamin D, n (%) 25 (59.5) 27 (50.9) 0.404
HOMA-IR the homeostasis model assessment index of insulin resistance, ACEI angiotensin I converting enzyme
inhibitors, ARB angiotensin II type-1 receptor antagonists






All-cause deaths 34 (81.0) 22 (41.5) < 0.001
Cardiac deaths 30 (71.4) 12 (22.6) < 0.001
Acute myocardial infarction death 7 (16.7) 0 (0) 0.002
Heart failure death 9 (21.4) 9 (17.0) 0.583
Sudden cardiac death 14 (33.3) 3 (5.7) <0.001
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for cardiac death was recognized in a whole SPECT (hazard
ratio, 1.044; 95 % CI, 1.013-1.075; p=0.005), and was found
in the LAD area (hazard ratio, 1.075; 95 % CI, 1.030-1.122;
p=0.001), but not in the LCX or RCA areas. However, in
comparison between BMIPP score and BMIPP-Tl mismatch
score using Cox hazard analysis, BMIPP SS (hazard ratio,
1.080; 95 % CI, 1.013-1.152, p=0.018) and total BMIPP
score in the LAD (hazard ratio, 1.185; 95 % CI, 1.046-
1.341; p=0.007) were more useful for prediction of cardiac
death than BMIPP-Tl mismatch score in a whole SPECT (haz-
ard ratio, 0.977; 95%CI0.918-1.039; p=0.453) and that in the
LAD area (hazard ratio, 0.916; 95 % CI 0.808-1.038; p=
0.170), respectively.
Impaired fatty acid imaging and left ventricular systolic
function BMIPP SS tended to be inversely related with LVEF
(r=-0.181, p=0.079), whereas Tl SS was not related with
LVEF (r=0.050, p=0.632). Further, LVEF tended to be
Table 3 Univariate Cox hazard
analysis for cardiac death Hazard ratio 95 % CI p
Age (1 year) 1.049 1.019-1.080 0.001
Male gender (0=female; 1=male) 0.990 0.539-1.820 0.975
Dialysis duration (1 month) 1.002 0.999-1.005 0.261
Smoking habit (0=no; 1=yes) 0.904 0.475-1.718 0.757
Alcohol consumption (0=no; 1=yes) 0.713 0.364-1.398 0.325
Diabetes mellitus (0=no; 1=yes) 0.981 0.522-1.846 0.953
Systolic blood pressure before dialysis (1 mmHg) 0.990 0.971-1.009 0.292
Diastolic blood pressure before dialysis (1 mmHg) 0.991 0.973-1.009 0.322
Body mass index (1 kg/m2) 0.903 0.839-0.971 0.006
Cardiothoracic ratio (1 %) 1.029 0.972-1.089 0.331
Left ventricular ejection fraction (1 %) 0.994 0.976-1.013 0.522
Left ventricular mass index (1 g/m2) 0.996 0.989-1.003 0.247
Blood hemoglobin (1 g/L) 0.990 0.963-1.018 0.497
Serum albumin (1 g/L) 0.891 0.818-0.970 0.008
Serum calcium (1 mmol/L) 0.545 0.072-4.103 0.555
Serum inorganic phosphorus (1 mmol/L) 0.487 0.209-1.134 0.095
Serum total cholesterol (1 mmol/L) 0.777 0.546-1.108 0.163
Log serum intact parathyroid hormone (1) 1.044 0.424-2.571 0.925
Serum C-reactive protein (1 mg/L) 0.923 0.827-1.030 0.151
Log plasma B-type natriuretic peptide (1) 0.660 0.307-1.418 0.287
HOMA-IR (1 mmol/L·μU/ml) 1.293 1.123-1.488 < 0.001
BMIPP summed scores (1) 1.057 1.026-1.089 < 0.001
BMIPP summed scores ≥ 12 (0=no; 1=yes) 13.368 4.122-43.361 < 0.001
Tl summed scores (1) 1.054 0.988-1.123 0.110
Focal pattern in BMIPP SPECT (0=no; 1=yes) 3.814 1.947-7.471 < 0.001
Medications
α1 blockers (0=no; 1=yes) 0.929 0.331-2.609 0.889
β blockers (0=no; 1=yes) 1.190 0.624-2.272 0.597
Calcium channel blockers (0=no; 1=yes) 0.903 0.468-1.739 0.760
ACEI (0=no; 1=yes) 1.827 0.248-13.343 0.554
ARB (0=no; 1=yes) 1.162 0.593-2.279 0.662
Nitrates (0=no; 1=yes) 0.804 0.316-2.046 0.647
Antiplatelet drugs (0=no; 1=yes) 1.091 0.591-2.013 0.780
Anticoagulation drugs (0=no; 1=yes) 1.450 0.199-10.595 0.714
Statins (0=no; 1=yes) 0.490 0.206-1.165 0.107
Vitamin D (0=no; 1=yes) 0.697 0.380-1.278 0.234
CI confidence interval; HOMA-IR the homeostasis model assessment index of insulin resistance; ACEI angio-
tensin I converting enzyme inhibitors; ARB angiotensin II type-1 receptor antagonist
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inversely associated with total BMIPP scores in the LAD area
(r=-0.201, p=0.051), but not in the LCX (r=-0.055, p=
0.599) or RCA (r=-0.030, p=0.776) areas.
Discussion
Of 95 patients who had BMIPP SS of six or more, focal
pattern was recognized in 42 (44.2 %), whereas non-focal
pattern was recognized in 53 (55.8 %). During follow up for
5.1±2.0 years, 42 patients died of cardiac events. The occur-
rence of cardiac deaths was higher in the focal than in the non-
focal group. In stepwise Cox hazard analysis, focal pattern
was associated with cardiac death independently of BMIPP
SS ≥ 12, a cutoff value predicting cardiac death in our previ-
ous studies [2, 6]. Cardiac death-free survival rates at 5 years
were lower in the focal than in the non-focal types. The mean
total BMIPP scores of the coronary territories were higher in
the focal than in the non-focal group in the LAD area, but not
in the RCA or LCX areas, and the predictive potential of
reduced uptake of BMIPP was stronger in the LAD area com-
pared with the RCA or LCX areas. These findings indicate
that not only severe impairment in BMIPP SPECT, but also
focally impaired myocardial fatty acid imaging in the LAD
area, could be strong risk factors for cardiac death in this
population.
123I-BMIPP is a branched free fatty acid (FFA) analogue
characterized by resistance to β-oxidation. Intravenously ad-
ministered BMIPP is incorporated from the blood into myo-
cardial cells via the CD36-positive FFA binding protein. In-
corporated BMIPP is acylated by resolution of adenosine tri-
phosphate (ATP). Acylated BMIPP is mostly accumulated in
the lipid pool, and a part of acylated BMIPP is metabolized to
ρ-iodophenyl acetic acid via α-oxidation or β-oxidation in
mitochondria. Of intracoronary administered BMIPP in ca-
nine myocardium, uptake into myocardial cells was 74 %,
and retention of acylated BMIPP in the lipid pool was
65.3 %, whereas metabolism via α-oxidation or β-oxidation
was only 8.7 %. BMIPP SPECT imaging is believed to reflect
intracardiac accumulation of acylated BMIPP in the lipid pool
and myocardial content of ATP [10–15].
Impaired fatty acid metabolism and consequent accumula-
tion of acyl CoA are characteristic of renal failure [16]. Accu-
mulated acyl CoAs inhibit glucose uptake by disruption of the
intracellular signaling cascade that moves the GLUT4 trans-
porter from its intracellular location to the surface of the myo-
cardial membrane [17, 18], and also inhibit enzymes impor-
tant in glucose metabolism such as pyruvate dehydrogenase
[19, 20]; accumulated acyl CoAs thereby enhance insulin re-
sistance. In our previous study, impaired fatty acidmetabolism
evaluated by BMIPP SPECTwas in proportion to HOMA-IR,
an indicator of insulin resistance, in diabetic and nondiabetic
hemodialysis patients without obstructive CAD [21]. There-
fore, impairment in BMIPP SPECT in hemodialysis patients
without obstructive CAD may indicate the reduction of myo-
cardial ATP synthesis via inhibition of not only fatty acid but
also glucose metabolism.
Mechanical stresses to the heart by continued pressure and/
or volume overloading and reduction of myocardial blood
supply are thought to be the main factors impairing myocar-
dial fatty acid metabolism in hemodialysis patients. Since the
former is inevitable in patients on maintenance hemodialysis,
myocardial fatty acid metabolism has a tendency to be im-
paired in this population. In pathological studies,
intramyocardial arteriolar thickening, reduced capillary
Table 4 Stepwise Cox hazard
analysis for cardiac death Hazard ratio 95 % CI p
Focal pattern in BMIPP SPECT (0=no; 1=yes) 2.258 1.136-4.486 0.020
BMIPP summed scores ≥12 (0=no; 1=yes) 8.712 2.546-29.808 0.001
Serum albumin (1 g/L) 0.882 0.792-0.981 0.021
HOMA-IR (1 mmol/L·μU/ml) 1.150 0.985-1.342 0.077
Body mass index (1 kg/m2) 0.940 0.877-1.008 0.082
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Fig. 3 Kaplan-Meier analysis of cardiac death-free survival of focal (n=
42) and non-focal (n=53) groups
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density, and myocardial fibrosis are unique findings of the
heart of hemodialysis patients [22–24]; these myocardial ab-
normalities can potentially cause myocardial microcirculatory
disturbance. These characteristics in hemodialysis patients
give rise to the result that the myocardial cells are more sus-
ceptible to reduced myocardial blood supply than in non-
dialysis patients, and lead to the impairment in myocardial
fatty acid metabolism. When significant obstructive coronary
lesions are not found, as in this study population, myocardial
microcirculation disorder may be the main factor causing sig-
nificant impairment of myocardial fatty acid metabolism.
In the present study, reduction of BMIPP in SPECT in the
LAD area strongly predicted cardiac death, as compared with
the areas of LCX or RCA. Since the LAD perfuses important
areas of the left ventricle as the pump function of the heart,
reduction in ATP synthesis in this perfusion area shown by
impaired BMIPP SPECTmight result in severe cardiac events
leading to cardiac deaths. What is the mechanism of focal
impairment in myocardial fatty acid metabolism? The relation
between endothelial dysfunction in the epicardial coronary
arteries and microcirculation disturbance in the coronary per-
fusion areas might partly explain the mechanism. Coronary
endothelial dysfunction is detected in some patients with min-
imally obstructive CAD [25]. Endothelium-dependent vaso-
dilation was less evident in a group with than without revers-
ible defects on myocardial perfusion images among patients
without significant obstructive CAD [26]. Prior studies have
demonstrated that coronary microvascular endothelial dys-
function may contribute to the reduced vasodilator reserve in
patients with minimally obstructive CAD [27, 28]. Hasdai
et al. reported that coronary endothelial dysfunction in
humans may cause dysfunction of microcirculation endothe-
lium of the coronary territory, which results in reduction of
myocardial blood flow [29]. Further, endothelial function was
impaired in isolated human uremic resistance arteries [30].
Endothelial dysfunction in the epicardial coronary arteries
might have caused myocardial microcirculation disturbance
via microcirculation endothelial dysfunction or spasm [31],
leading to impairment in myocardial fatty acid metabolism
in the coronary perfusion areas.
Slim et al. reported that location of defect on exercise or
pharmacological stress myocardial perfusion imaging was not
associated with future hard cardiac events such as cardiac
death or non-fatal myocardial infarction in patients with
known or suspected coronary artery disease [32]. The differ-
ence in the results obtained by Slim et al. and ourselves might
















Fig. 5 Receiver operating characteristic analysis regarding the predictive
potential for cardiac death by coronary territorial impairment in BMIPP
SPECT. The area under the curve: LAD, 0.818; LCX, 0.582; RCA, 0.478.
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Fig. 4 Kaplan-Meier analyses of
cardiac death-free survival in
focal and non-focal groups by
types of cardiac deaths. MI,
myocardial infarction
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perfusion imaging and fatty acid imaging, and that between
the patient populations (non-dialysis and dialysis patients).
Matsuki et al. previously reported that the predictive potential
for the hard cardiac events was higher in BMIPP SPECT than
stress myocardial perfusion SPECT, and BMIPP SPECT im-
aging had excellent negative predictive values in patients with
angina [33]. Because BMIPP SPECT is believed to reflect
myocardial ATP synthesis [10–15], regional reduction in
myocardial energy supply in an important coronary territory
area such as LAD might be associated with cardiac prognosis
particularly in hemodialysis patients, although stress myocar-
dial perfusion imaging is also useful for risk stratification of
cardiovascular events in this population [34, 35]. In the pres-
ent study, BMIPP SS tended to be inversely related with
LVEF, whereas Tl SS was not related with LVEF. Further-
more, LVEF tended to be inversely associated with total
BMIPP scores in the LAD area, but not in the LCX or RCA
areas. Since LVEF is one of the major predictors for cardio-
vascular events in asymptomatic hemodialysis patients [36],
this relation between impaired BMIPP uptake and left ventric-
ular systolic dysfunction may contribute to explaining in part
how impaired fatty acid imaging in the LAD area could be
associated with cardiac death. Further investigation is needed
to clarify this important issue.
This study has several limitations. We used CAG to con-
firm the presence of suspected myocardial ischemia in the
patients. The inclusion criterion of Bwithout significant ob-
structive coronary artery disease^ does not necessarily mean
that the epicardial coronary arteries were normal. Since histo-
pathological and intravascular ultrasound studies have dem-
onstrated the propensity of angiography to underestimate
lesional severity [37, 38], we cannot exclude the possibility
that some angiographically non-significant lesions were flow
limiting. We used HOMA-IR to evaluate levels of insulin
resistance. Although others have shown that HOMA-IR close-
ly correlates with clamp-measured insulin resistance in pa-
tients with or without diabetes mellitus, including those with
chronic renal failure [39], the use of HOMA-IR can be con-
sidered as a limitation of this study. We did not investigate the
relation between regional wall motion of the left ventricle and
uptake of BMIPP and/or Tl in SPECT. Since this study was a
retrospective analysis of a previous cohort study [6], we could
not define the predictive value of focal impairment of BMIPP
SPECT for cardiac deaths.
The results of this study showed that impaired patterns, as
well as the severity of impairment in myocardial fatty acid
imaging, may be useful in the prediction of cardiac deaths in
hemodialysis patients without obstructive CAD. Particularly,
focal impairment in BMIPP SPECT in the LAD area would
strongly predict future cardiac death, especially acute MI
death or SCD. In the multicenter cohort study B-SAFE, the
significance of BMIPP SPECT in cardiac death was demon-
strated in hemodialysis patients [4]. The results in this study
would further strengthen the usefulness of BMIPP SPECT for
risk stratification of cardiac deaths in hemodialysis patients
who have potentially high risk for cardiovascular events.
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